Scinai shares surge 11.35% premarket as immunotherapy advances enhance tumor-fighting potential and personalize cancer treatments.

Scinai Immunotherapeutics surged 11.35% in premarket trading following the announcement of advancements in its immunotherapy platform for cancer treatment. The company highlighted its ability to enhance immune system effectiveness against tumors through proprietary biotechnological methods, including personalized treatment plans and rigorous clinical trials. The news emphasized potential improvements in patient survival rates and the development of dual-action agents that activate immune responses and create lasting memory against cancer cells. These innovations, coupled with strategic collaborations and a focus on research funding, position Scinai as a leader in oncology, directly aligning with the premarket rally driven by optimism over its therapeutic pipeline and market differentiation.